CompletedPhase 2NCT03950050

Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy

Studying Gaucher disease

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Shaare Zedek Medical Center
Principal Investigator
Ari Zimran
Ari Zimran - Shaare Zedek
Intervention
Ambroxol(drug)
Enrollment
40 enrolled
Eligibility
18-75 years · All sexes
Timeline
2019 – 2022

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03950050 on ClinicalTrials.gov

Other trials for Gaucher disease

Additional recruiting or active studies for the same condition.

See all trials for Gaucher disease →

← Back to all trials